Table 1.
Patient and baseline tumor characteristics
| Factor | Number (%) |
|---|---|
| All | 183 (100) |
| Median age, years (range) 49 (25-70) | |
| Age (y) | |
| ≤ 50 | 116 (63.4) |
| > 50 | 68 (36.6) |
| Menstrual status | |
| Premenopausal | 106 (57.9) |
| Postmenopausal | 77 (42.1) |
| Clinical stage | |
| II | 70 (38.3) |
| III | 113 (61.7) |
| Tumor size (cm) | |
| ≤ 2.0 | 49 (26.8) |
| > 2.0 | 134 (73.2) |
| Clinical lymph node status | |
| Negative | 62 (33.9) |
| Positive | 121 (66.1) |
| Histological grade | |
| G1 | 32 (17.5) |
| G2 | 70 (38.3) |
| G3 | 81 (44.2) |
| HR, HER2 subtype | |
| HR- HER2+ | 122 (66.7) |
| HR- HER2- | 61 (33.3) |
| Ki67 status | |
| Low (< 14%) | 45 (24.6) |
| Intermediate (14-30%) | 60 (32.8) |
| High (> 30%) | 78 (42.6) |
| Neoadjuvant treatment | |
| FEC | 90 (49.2) |
| TEC | 55 (30.1) |
| AC followed by T | 38 (20.7) |
| Clinical response | |
| CR/PR | 156 (85.2) |
| SD/PD | 27 (14.8) |
| Pathological response | |
| pCR | 35 (19.1) |
| non-pCR | 148 (80.9) |
HR, hormone receptor; HER-2, human epidermal receptor 2; FEC, 5-fluorouracil. + epirubicin + cyclophosphamide; TEC, docetaxel + epirubicin + cyclophosphamide; AC followed by T, doxorubicin + cyclophosphamide followed by docetaxel; CR/CR, complete response or partial response; SD/PD, stable disease or progression of disease; pCR, pathological complete response. HER-2, human epidermal receptor 2.